The FDA Antiviral Drugs Advisory Committee voted 13 to 1 in favor of approval for Gilead Inc.'s single-tablet Quad regimen (elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil fumarate) for treatment-naive adult patients with HIV-1 Friday after a day-long deliberation that exhaustively examined the issue of renal impairment.